What is Emergent Biosolutions's EV / EBITDA?

Emergent Biosolutions (EBS) reported EV / EBITDA of 4.1× in Q3 2025.

What is the long-term trend for Emergent Biosolutions's EV / EBITDA?

Over 2 years (2020 to 2024), Emergent Biosolutions's EV / EBITDA has grown at a 3364.2% compound annual growth rate (CAGR), from 9.1× to 10,885×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Emergent Biosolutions EBS EV / EBITDA

EV / EBITDA at other companies

Thermo Fisher ScientificTMO

21.3×-3.5×

Regeneron PharmaceuticalsREGN

19.5×+3.6×

AMP

Amphastar PharmaceuticalsAMPH

8.1×+0.6×

CorMedixCRMD

4.7×—

Collegium Pharmaceutical, Inc.COLL

3.1×+0.5×

West Pharmaceutical ServicesWST

21.5×-1.1×

Other financials

Income statement

See full

Revenue$156.1M-29.7%

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Calculated from Emergent Biosolutions’s reported figures.

enterprise value/ebitda=4.1×

Based on the most recent quarter.

The official record: Emergent Biosolutions’s 10-Q, filed October 30, 2025, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's EV / EBITDA?: Emergent Biosolutions (EBS) reported EV / EBITDA of 4.1× in Q3 2025.
What is the long-term trend for Emergent Biosolutions's EV / EBITDA?: Over 2 years (2020 to 2024), Emergent Biosolutions's EV / EBITDA has grown at a 3364.2% compound annual growth rate (CAGR), from 9.1× to 10,885×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.